You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 12,440,474

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,440,474

Title:	Stable pharmaceutical compositions of clonidine
Abstract:	The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.
Inventor(s):	Shailendra Mandge, Harish GUNDA, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, BALASUBRAMANIAN Satheesh, Sumitra Ashokkumar PILLAI
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US19/021,882
Patent Claims:	1. A liquid pharmaceutical composition consisting of: (a) clonidine hydrochloride at a concentration of about 20 μg/mL; (b) stabilizer at a concentration of about 0.001% to 20% w/w, based on total weight of the composition; (c) a preservative at a concentration of about 0.01% to 5.0% w/w, based on total weight of the composition; (d) a sweetener; (e) a flavoring agent; and (f) water; and (g) optionally, a pH adjusting agent; wherein said composition is free of buffer; wherein said composition is an oral solution; and wherein not more than 2% w/w of total impurities are formed when said composition is stored for at least 3 months at 25° C./40% RH or 25° C./60% RH. 2. The liquid pharmaceutical composition according to claim 1, wherein the said stabilizer is selected from the group consisting histidine, arginine, meglumine, tromethamine, sodium chloride or mixtures thereof. 3. The liquid pharmaceutical composition according to claim 1, wherein the preservative is potassium sorbate and/or sodium propionate at a concentration of 2.5 mg/mL. 4. The liquid pharmaceutical composition according to claim 1, wherein the sweetener is sucralose. 5. The liquid pharmaceutical composition according to claim 1, wherein the pH is from about 3 to about 9. 6. The liquid pharmaceutical composition according to claim 1, wherein the pH is from about 4 to about 6. 7. The liquid pharmaceutical composition according to claim 1, wherein a concentration of the stabilizer is from 01% to 15.0% w/w, based on total weight of the composition. 8. The liquid pharmaceutical composition according to claim 1, wherein a concentration of the stabilizer is from 0.1% to 10.0% w/w, based on total weight of the composition. 9. The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to stabilizer ranges from about 1:50 to about 1:150. 10. The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to stabilizer is about 1:125. 11. The liquid pharmaceutical composition according to claim 1, wherein a concentration of the preservative ranges from 0.05% to 1.0%, based on total weight of the composition. 12. The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to preservative is from about 1:20 to about 1:70. 13. The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to preservative is about 1:50. 14. The liquid pharmaceutical composition according to claim 1, wherein said composition exhibits in-use shelf life of at least one month when stored at room temperature. 15. A multi-dose container comprising the liquid pharmaceutical composition according to claim 1. 16. A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container is a polyethylene terephthalate (PET) bottle. 17. A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container is a high-density polyethylene (HDPE) bottle. 18. A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container is a glass bottle. 19. A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container comprises blow-fill sealed vials.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.